Apixaban

Hospital Pharmacy

Volumn 48, Issue 6, 2013, Pages 494-509

  Cada, Dennis J ^c   Levien, Terri L ^a   Baker, Danial E ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Drug Information Center   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; ENOXAPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; PATIENT PREFERENCE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

EID: 84878578132     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4806-494     Document Type: Review

References (33)

1. Eliquis [package insert]. Princeton, NJ: Bristol-Myers Squibb; December 2012.
2. Apixaban. ClinicalTrials.gov Web site. http://www.clinicaltrials. gov. Accessed January 7, 2013.
3. Roser-Jones C, Becker RC. Apixaban: An emerging oral factor Xa inhibitor. J Thromb Thrombolysis. 2010;29(1):141-146.
4. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008;29(2):155-165.
5. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1-22.
6. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007; 5(12):2368-2375.
7. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement [published correction appears N Engl J Med. 2009;361(6): 594-604.
8. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomized double-blind trial. Lancet. 2010;375(9717):807-815.
9. Buller H, Deitchman D, Prins M, Segers A. Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6(8):1313-1318.
10. Lopes RD, Alexander JH, Al-Khatib SM, et al ARISTOTLE Investigators. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale [published correction appears Am Heart J. 2010; 159(3):331-339.
11. Alexander JH, Becker RC, Bhatt DL, et al APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877-2885.
12. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: Single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):476-487.
13. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.
14. Furie KL, Goldstein LB, Albers GW, et al American Heart Association Stroke Council; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: A science advisory for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2012;43(12):3442-3453.
15. Granger CB, Alexander JH, McMurray JJ, et al ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-992.
16. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomised controlled trial [published correction appears Lancet. 2012; 380(9855):1749-1758.
17. Connolly S, Eikelboom J, Joyner C, et al AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.
18. Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: The apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke. 2012;43(12):3291-3297.
19. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of APIXABAN in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012; 21(6):429-435.
20. Falck-Ytter Y, Francis CW, Johanson NA, et al American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e278S-e325S
21. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487-2498.
22. Guyatt GH, Norris SL, Schulman S, et al American College of Chest Physicians. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141((2)(suppl 2)):53S-70S
23. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011; 365(23):2167-2177.
24. Kearon C, Akl EA, Comerota AJ, et al American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141((2)(suppl)): e419Se494S
25. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708.
26. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/ AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published online ahead of print December 17, 2012]. J Am Coll Cardiol. 2013;61(4):e78-e140.
27. Jneid H, Anderson JL, Wright RS, et al; 2012 Writing Committee Members. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/ non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126(7):875-910.
28. Alexander JH, Lopes RD, James S, et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708.
29. Temple R. NDA approval letter: Eliquis (apixaban NDA 202155). US Food and Drug Administration Web site. http:// www.accessdata.fda.gov/drugsatfda-docs/ appletter/2012/ 202155Orig1s000ltr.pdf. Published December 28, 2012. Accessed January 2, 2013.
30. Bristol-Myers Squibb. Eliquis (apixaban) tablets REMS document. US Food and Drug Administration Web site. http:// www.fda.gov/downloads/Drugs/ DrugSafety/PostmarketDrug- SafetyInformationforPatientsandProviders/UCM333723. pdf. Published December 2012. Accessed January 14, 2013.
31. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; November 2012.
32. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; January 2013.
33. Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb; October 2011.